.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Merck
Moodys
US Department of Justice
Cerilliant
Medtronic
Boehringer Ingelheim
Chubb
Covington
Healthtrust

Generated: September 23, 2017

DrugPatentWatch Database Preview

Sunovion Company Profile

« Back to Dashboard

What is the competitive landscape for SUNOVION, and what generic alternatives to SUNOVION drugs are available?

SUNOVION has nine approved drugs.

There are forty-two US patents protecting SUNOVION drugs on SUNOVION drugs in the past three years.

There are five hundred and thirty-eight patent family members on SUNOVION drugs in forty-seven countries.

Summary for Applicant: Sunovion

Patents:42
Tradenames:9
Ingredients:9
NDAs:9
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sunovion Pharms Inc
LATUDA
lurasidone hydrochloride
TABLET;ORAL200603-003Dec 7, 2011RXYesNo► Subscribe► SubscribeY► Subscribe
Sunovion Pharms Inc
APTIOM
eslicarbazepine acetate
TABLET;ORAL022416-003Nov 8, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Sunovion Pharms Inc
LATUDA
lurasidone hydrochloride
TABLET;ORAL200603-004Apr 26, 2012RXYesNo► Subscribe► SubscribeY► Subscribe
Sunovion Pharms Inc
SEEBRI
glycopyrrolate
POWDER;INHALATION207923-001Oct 29, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Sunovion Pharms Inc
UTIBRON
glycopyrrolate ; indacaterol maleate
POWDER;INHALATION207930-001Oct 29, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Sunovion Pharms Inc
SEEBRI
glycopyrrolate
POWDER;INHALATION207923-001Oct 29, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Sunovion Pharms Inc
LATUDA
lurasidone hydrochloride
TABLET;ORAL200603-003Dec 7, 2011RXYesNo► Subscribe► SubscribeY► Subscribe
Sunovion Pharms Inc
UTIBRON
glycopyrrolate ; indacaterol maleate
POWDER;INHALATION207930-001Oct 29, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Sunovion Pharms Inc
LATUDA
lurasidone hydrochloride
TABLET;ORAL200603-001Oct 28, 2010RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Sunovion

Paragraph IV activity for SUNOVION drugs

Drugname Dosage Strength Tradename Submissiondate
lurasidone hydrochloride
Tablets20 mg, 40 mg, 60 mg, 80 mg, and 120 mg
LATUDA
10/28/2014
arformoterol tartrate
Inhalation SolutionEq. 0.015 mg base/2 mL
BROVANA
10/1/2009
eszopiclone
Tablets1 mg, 2 mg and 3 mg
LUNESTA
12/15/2008

Non-Orange Book Patents for Sunovion

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,622,483.beta.2-adrenoceptor agonists► Subscribe
6,884,794 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets► Subscribe
8,436,017Beta-2-adrenoreceptor agonists► Subscribe
8,114,912Bronchodilating .beta.-agonist compositions and methods► Subscribe
8,288,532Asymmetric catalytic reduction of oxcarbazepine► Subscribe
8,623,922Bronchodilating Beta-agonist compositions and methods► Subscribe
5,780,632 Imide derivatives and their production and use► Subscribe
7,732,641Formoterol tartrate process and polymorph► Subscribe
8,101,160Formulations for use in inhaler devices► Subscribe
7,223,748Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Sunovion Drugs

Country Document Number Estimated Expiration
Canada2616984► Subscribe
South Korea20080103614► Subscribe
New Zealand565462► Subscribe
Germany60327634► Subscribe
Denmark1274406► Subscribe
Canada2180301► Subscribe
Denmark1663155► Subscribe
Portugal1719505► Subscribe
Cyprus1115304► Subscribe
United Kingdom0109432► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Sunovion Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90057-5Sweden► SubscribePRODUCT NAME: LURASIDONE, OPTIONALLY IN THE FORM OF LURASIDONE HYDROCHLORIDE; REG. NO/DATE: EU/1/14/913 20140327
0140030 00118Estonia► SubscribePRODUCT NAME: LURASIDOON;REG NO/DATE: K(2014)2046 (LOPLIK) 27.03.2014
2010 00006Denmark► Subscribe
1267866/01Switzerland► SubscribeFORMER REPRESENTATIVE: VOSSIUS AND PARTNER, CH
2014000092Germany► SubscribePRODUCT NAME: LURASIDON, INSBESONDERE EINE PHARMAZEUTISCH VERTRAEGLICHE SALZFORM UND IM SPEZIELLEN DAS HYDROCHLORIDSALZ DAVON; REGISTRATION NO/DATE: EU/1/14/913/001-021 20140321
166Luxembourg► SubscribePRODUCT NAME: GLYCOPYRRONIUM OU UN DE SES SELS
0Finland► Subscribe
3Finland► Subscribe
1 5024-2014Slovakia► SubscribePRODUCT NAME: LURASIDON; REGISTRATION NO/DATE: EU/14/913/001 - EU/14/913/021 20140327
C0006France► SubscribePRODUCT NAME: INDACATEROL OU UN SEL DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/09/593/001 DU 20091130; REGISTRATION NO/DATE AT EEC: EU/1/09/593/001-010 DU 20091130
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Accenture
Julphar
UBS
Baxter
Cipla
Johnson and Johnson
Farmers Insurance
Moodys
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot